Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. European Lung Cancer Congress 2022

Janssen Pharmaceutica - Evolving treatment options and practices in EGFR-mutant NSCLC

Discussion - Unmet needs in the management of EGFR+ NSCLC

Date

31 Mar 2022

Session

Janssen Pharmaceutica - Evolving treatment options and practices in EGFR-mutant NSCLC

Presenters

Benjamin Besse

Authors

B. Besse1, N. Leighl2

Author affiliations

  • 1 Institut Gustave Roussy, Villejuif/FR
  • 2 UHN - University Health Network - Princess Margaret Cancer Center, Toronto/CA

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Welcome and introductions

Presenter: Antonio Passaro

Session: Janssen Pharmaceutica - Evolving treatment options and practices in EGFR-mutant NSCLC

Resources:

Webcast

Live Q&A

Presenter: Enriqueta Felip

Session: Janssen Pharmaceutica - Evolving treatment options and practices in EGFR-mutant NSCLC

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.